^
Association details:
| Biomarker: | RAD51C mutation |
|---|---|
| Cancer: | Peritoneal Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical insights from the rucaparib access program in Spain: A sub-analysis of long-term responders by GEICO.
Published date:
05/26/2022
Excerpt:
Adult women with HGOC, fallopian tube, or primary peritoneal cancer were included and received rucaparib (600 mg BID) in the MTN, Tx Pt-sensitive or Tx Pt-resistant setting....In the Tx group, 10 patients (30.3%) were LTR, with a median age of 71 years (47-86). All of them harbored BRCA and/or RAD51C mutations.
DOI:
10.1200/JCO.2022.40.16_suppl.e17562
